• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Tuesday's Pre-Market Session

    10/17/23 9:06:03 AM ET
    $AHG
    $ASMB
    $ATHX
    $EVLO
    Real Estate
    Real Estate
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AHG alert in real time by email

    Gainers

    • Assembly Biosciences (NASDAQ:ASMB) shares increased by 108.0% to $1.51 during Tuesday's pre-market session. The company's market cap stands at $79.4 million.
    • Olink Holding (NASDAQ:OLK) stock moved upwards by 67.22% to $25.05. The market value of their outstanding shares is at $3.1 billion.
    • Athersys (NASDAQ:ATHX) shares moved upwards by 33.84% to $0.13. The market value of their outstanding shares is at $3.5 million.
    • Monte Rosa Therapeutics (NASDAQ:GLUE) stock rose 16.58% to $5.83. The company's market cap stands at $289.4 million.
    • Akso Health Group (NASDAQ:AHG) shares rose 16.21% to $2.15. The company's market cap stands at $49.1 million.
    • Vigil Neuroscience (NASDAQ:VIGL) shares moved upwards by 13.38% to $7.0. The market value of their outstanding shares is at $250.9 million.

    Losers

    • Evelo Biosciences (NASDAQ:EVLO) shares decreased by 55.3% to $1.3 during Tuesday's pre-market session. The market value of their outstanding shares is at $24.4 million.
    • Purple Biotech (NASDAQ:PPBT) shares declined by 13.8% to $1.25. The company's market cap stands at $26.7 million.
    • Redhill Biopharma (NASDAQ:RDHL) shares fell 13.36% to $0.37. The market value of their outstanding shares is at $2.1 million.
    • Kodiak Sciences (NASDAQ:KOD) shares decreased by 12.47% to $1.51. The company's market cap stands at $79.2 million.
    • Processa Pharma (NASDAQ:PCSA) shares fell 12.27% to $0.49. The market value of their outstanding shares is at $12.0 million.
    • XTL Biopharmaceuticals (NASDAQ:XTLB) shares decreased by 11.75% to $0.75. The market value of their outstanding shares is at $4.1 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $AHG alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AHG
    $ASMB
    $ATHX
    $EVLO

    CompanyDatePrice TargetRatingAnalyst
    Kodiak Sciences Inc
    $KOD
    11/11/2025$24.00Neutral → Buy
    H.C. Wainwright
    Kodiak Sciences Inc
    $KOD
    10/24/2025$24.00Neutral → Overweight
    Analyst
    Kodiak Sciences Inc
    $KOD
    9/25/2025$17.00Underweight → Equal Weight
    Barclays
    Assembly Biosciences Inc.
    $ASMB
    9/24/2025$38.00Mkt Outperform
    Citizens JMP
    Kodiak Sciences Inc
    $KOD
    9/22/2025$15.00Buy
    Jefferies
    Assembly Biosciences Inc.
    $ASMB
    8/18/2025$50.00Buy
    H.C. Wainwright
    Kodiak Sciences Inc
    $KOD
    8/14/2025$15.00Underweight → Neutral
    Analyst
    Vigil Neuroscience Inc.
    $VIGL
    5/28/2025$8.00Buy → Hold
    Stifel
    More analyst ratings

    $AHG
    $ASMB
    $ATHX
    $EVLO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Kodiak Sciences upgraded by H.C. Wainwright with a new price target

    H.C. Wainwright upgraded Kodiak Sciences from Neutral to Buy and set a new price target of $24.00

    11/11/25 8:00:12 AM ET
    $KOD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Kodiak Sciences upgraded by Analyst with a new price target

    Analyst upgraded Kodiak Sciences from Neutral to Overweight and set a new price target of $24.00

    10/24/25 8:56:02 AM ET
    $KOD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Kodiak Sciences upgraded by Barclays with a new price target

    Barclays upgraded Kodiak Sciences from Underweight to Equal Weight and set a new price target of $17.00

    9/25/25 8:23:23 AM ET
    $KOD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AHG
    $ASMB
    $ATHX
    $EVLO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Principal Accounting Officer Dunn Edmund sold $2,496 worth of shares (139 units at $17.96), decreasing direct ownership by 0.61% to 22,554 units (SEC Form 4)

    4 - Monte Rosa Therapeutics, Inc. (0001826457) (Issuer)

    3/5/26 5:24:23 PM ET
    $GLUE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    President & CEO Warmuth Markus sold $97,974 worth of shares (5,466 units at $17.92), decreasing direct ownership by 0.88% to 613,471 units (SEC Form 4)

    4 - Monte Rosa Therapeutics, Inc. (0001826457) (Issuer)

    3/4/26 4:50:05 PM ET
    $GLUE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Principal Accounting Officer Dunn Edmund exercised 25,700 shares at a strike of $13.41 and sold $464,886 worth of shares (25,700 units at $18.09) (SEC Form 4)

    4 - Monte Rosa Therapeutics, Inc. (0001826457) (Issuer)

    3/2/26 5:02:46 PM ET
    $GLUE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AHG
    $ASMB
    $ATHX
    $EVLO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Baker Bros. Advisors Lp bought $60,000,008 worth of shares (2,608,696 units at $23.00) (SEC Form 4)

    4 - Kodiak Sciences Inc. (0001468748) (Issuer)

    12/19/25 4:06:09 PM ET
    $KOD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Large owner Gilead Sciences, Inc. bought 2,295,920 shares, increasing direct ownership by 104% to 4,505,391 units (SEC Form 4)

    4 - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Issuer)

    10/3/25 4:30:21 PM ET
    $ASMB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Leo Chandra P. bought $58,383 worth of shares (10,000 units at $5.84) (SEC Form 4)

    4 - Monte Rosa Therapeutics, Inc. (0001826457) (Issuer)

    3/25/25 6:32:00 PM ET
    $GLUE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AHG
    $ASMB
    $ATHX
    $EVLO
    SEC Filings

    View All

    SEC Form 6-K filed by XTL Biopharmaceuticals Ltd.

    6-K - XTL BIOPHARMACEUTICALS LTD (0001023549) (Filer)

    3/10/26 4:05:03 PM ET
    $XTLB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Redhill Biopharma Ltd.

    6-K - RedHill Biopharma Ltd. (0001553846) (Filer)

    3/5/26 9:00:19 AM ET
    $RDHL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by XTL Biopharmaceuticals Ltd.

    6-K - XTL BIOPHARMACEUTICALS LTD (0001023549) (Filer)

    2/27/26 4:34:26 PM ET
    $XTLB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AHG
    $ASMB
    $ATHX
    $EVLO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    H. pylori Infections Market in the 6MM to Observe Stupendous Growth at a CAGR of 9.5% During the Forecast Period (2026-2036) | DelveInsight

    The H. pylori infection market is evolving as treatment strategies shift toward optimized, targeted combination therapies, including triple- and quadruple-drug regimens, bismuth-based therapies, and novel emerging therapies such as Rifasutenizol (TenNor Therapeutics), Linaprazan glurate (Cinclus Pharma), Tegoprazan (RQ-00000004) (RaQualia Pharma/HK inno.N/Sebela Pharmaceuticals), and others, driven by improved eradication rates and safety profiles.LAS VEGAS, March 4, 2026 /PRNewswire/ -- Recently published H. pylori Infections Market Insights report includes a comprehensive understanding of current treatment practices, H. pylori infections emerging drugs, market share of individual therapies

    3/4/26 5:46:00 PM ET
    $CPIX
    $PHAT
    $RDHL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Biliary Tract Cancer Market is Predicted to Exhibit Remarkable Growth at a CAGR of 10.1% During the Forecast Period (2025-2034) | DelveInsight

    LAS VEGAS, March 2, 2026 /PRNewswire/ -- The biliary tract cancer market is experiencing steady growth driven by rising global incidence and improved diagnostic capabilities. Increasing adoption of targeted therapies and immuno-oncology approaches is expanding treatment options. Additionally, the launch of emerging drugs such as Tinengotinib (TransThera Sciences), Rilvegostomig (AstraZeneca), Nanvuranlat (JPH203) (J-Pharma/OHARA Pharmaceutical), Tovecimig (CTX-009) (Compass Therapeutics), Lenvatinib mesylate (LENVIMA) (Merck/Eisai), and others will further boost the market growth. Recently published Biliary Tract Cancer Market Insights report includes a comprehensive understanding of current

    3/2/26 5:31:00 PM ET
    $BOLD
    $CMPX
    $INCY
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
    Biotechnology: Commercial Physical & Biological Resarch

    XTL Announces Receipt of Staff Delist Determination from Nasdaq and Plans to Request Hearing

    RAMAT GAN, ISRAEL, Feb. 27, 2026 (GLOBE NEWSWIRE) -- XTL Biopharmaceuticals Ltd. (NASDAQ:XTLB) (TASE:XTLB.TA) (the "Company" or "XTL"), announced today that it has received a letter (the "Letter") from The Listing Qualifications Department (the "Staff") of The Nasdaq Stock Market LLC ("Nasdaq"), dated February 25, 2026, notifying the Company of the Staff's belief, based upon its review of the Company and pursuant to Nasdaq Listing Rule 5101, that the Company is a "public shell", and that continued listing of the Company's American Depositary Shares ("ADSs") is no longer warranted. The Company intends to request a hearing (the "Hearing") to appeal the delisting process before a Nasdaq Heari

    2/27/26 4:30:00 PM ET
    $XTLB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AHG
    $ASMB
    $ATHX
    $EVLO
    Leadership Updates

    Live Leadership Updates

    View All

    XTL Announces Receipt of Staff Delist Determination from Nasdaq and Plans to Request Hearing

    RAMAT GAN, ISRAEL, Feb. 27, 2026 (GLOBE NEWSWIRE) -- XTL Biopharmaceuticals Ltd. (NASDAQ:XTLB) (TASE:XTLB.TA) (the "Company" or "XTL"), announced today that it has received a letter (the "Letter") from The Listing Qualifications Department (the "Staff") of The Nasdaq Stock Market LLC ("Nasdaq"), dated February 25, 2026, notifying the Company of the Staff's belief, based upon its review of the Company and pursuant to Nasdaq Listing Rule 5101, that the Company is a "public shell", and that continued listing of the Company's American Depositary Shares ("ADSs") is no longer warranted. The Company intends to request a hearing (the "Hearing") to appeal the delisting process before a Nasdaq Heari

    2/27/26 4:30:00 PM ET
    $XTLB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Purple Biotech Highlights Significant Advantages of the Novel CAPTN-3 Tri-Specific Antibody Platform at the EACR 2025 Annual Congress

    REHOVOT, Israel, June 23, 2025 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that seek to overcome tumor immune evasion and drug resistance, today announced the presentation of new preclinical data on its novel CAPTN-3 tri-specific antibody platform in a poster presentation at the 2025 Annual Congress of the European Association for Cancer Research (EACR 2025), that was held in Lisbon, Portugal from June 16-19, 2025. "Purple's proprietary CAPTN-3 platform of T-cell engagers enables the creation of a large number of antibodies to different targets, and by capping the anti-CD3 a

    6/23/25 7:00:00 AM ET
    $PPBT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Purple Biotech Reports First Quarter 2025 Financial Results

    Final CM24 Phase 2 data presented at AACR Annual Meeting 2025, strengthening patient selection strategy for CM24 Phase 2b study planned to be initiated in Second Half of 2025 NT219 data presented at AACR Annual Meeting 2025; NT219 Phase 2 study in head and neck cancer on track to be initiated in First Half of 2025 CAPTN-3 differentiated T-cells and NK cells engagers tri-specific platform advances toward first-in-human clinical trials REHOVOT, Israel, May 21, 2025 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that seek to overcome tumor immune evasion and drug resistance, annou

    5/21/25 7:10:40 AM ET
    $PPBT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AHG
    $ASMB
    $ATHX
    $EVLO
    Financials

    Live finance-specific insights

    View All

    Monte Rosa Therapeutics Announces Positive Interim Phase 1 Data of MRT-8102 Demonstrating Profound CRP Reductions in Elevated CVD-risk Subjects

    In subjects with elevated cardiovascular disease (CVD) risk, MRT-8102, a NEK7-directed molecular glue degrader in development for the treatment of NLRP3/IL-1/IL-6 driven inflammatory diseases, demonstrated rapid and durable reductions in systemic inflammation  After four weeks of MRT-8102 treatment, C-reactive protein (CRP) levels were reduced by 85%, and 94% of study participants achieved CRP values below 2 mg/L, a threshold associated with reduced cardiovascular disease (CVD) risk Single ascending dose (SAD) and multiple ascending dose (MAD) cohorts demonstrated deep and sustained NEK7 degradation at doses from 5 mg to 400 mg Favorable safety profile observed with mild to moderate adve

    1/7/26 7:00:00 AM ET
    $GLUE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Monte Rosa Therapeutics to Present Interim MRT-8102 Phase 1 Study Results

    BOSTON, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that management will host a live conference call and webcast on Wednesday, January 7, at 8:00 a.m. ET. The webcast presentation will highlight interim clinical results from the ongoing Phase 1 study of the NEK7-directed MGD MRT-8102, including interim data from the ongoing Part 3 CRP proof-of-concept cohort in subjects with elevated cardiovascular disease risk. A webcast of the presentation will be accessible via the "Events & Presentations" section of Monte Rosa's website at ir.montero

    1/6/26 4:05:00 PM ET
    $GLUE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Monte Rosa Therapeutics Announces Compelling Clinical Activity of MRT-2359 in Combination with Enzalutamide in Heavily Pretreated Metastatic Castration-Resistant Prostate Cancer Patients with Androgen Receptor Mutations

    In mCRPC patients with androgen receptor (AR) mutations, treatment with MRT-2359 in combination with enzalutamide led to a 100% PSA response rate (4 of 4 patients) and a 100% disease control rate, including 2 patients with RECIST responses and 2 with stable disease  Combination of MRT-2359 and enzalutamide was generally well-tolerated with primarily Grade 1-2 adverse events Company plans to initiate a new, signal-confirming Phase 2 study of MRT-2359 targeting AR mutant and AR signaling-dependent patients in 2026 Updated MRT-2359 data expected to be presented at ASCO Genitourinary Cancers Symposium in February 2026 Conference call and webcast planned for today at 8 a.m. ET BOSTON, Dec

    12/16/25 7:00:00 AM ET
    $GLUE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AHG
    $ASMB
    $ATHX
    $EVLO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Purple Biotech Ltd.

    SC 13G/A - PURPLE BIOTECH LTD. (0001614744) (Subject)

    11/14/24 5:21:29 PM ET
    $PPBT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Vigil Neuroscience Inc.

    SC 13G/A - Vigil Neuroscience, Inc. (0001827087) (Subject)

    11/14/24 4:19:18 PM ET
    $VIGL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by Assembly Biosciences Inc.

    SC 13G - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Subject)

    11/14/24 3:22:29 PM ET
    $ASMB
    Biotechnology: Pharmaceutical Preparations
    Health Care